Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; none of the 23 sources its claims cite is checked for support yet.
Abstract
Background: Plasmodium vivax resistance to chloroquine (CQ) has been reported worldwide, although the World Health Organization clinical drug efficacy studies protocol does not permit classification of patient outcomes. Methods: We enrolled 40 patients with P. vivax malaria in northeastern Cambodia, where >17% treatment failures were previously reported. Patients were treated with CQ (30 mg/kg) and followed for 2 months, with frequent clinical examination and capillary blood sample collection for microscopy, molecular parasite detection and genotyping, and drug concentration measurements. Reinfections were prevented by relocating patients to a transmission-free area. Results: P. vivax parasites were eliminated in all patients by day 3. Genomic analyses revealed that all clones in polyclonal infections were cleared at the same rate, indicating their equal susceptibility to CQ. CQ blood concentrations were below the therapeutic level in all recurrent infections (24 of 40 patients), which were efficiently cleared by a second course of CQ treatment. Genotyping (128 SNPs barcode) and sequences of entire parasite genome (Whole-Genome Sequencing, Illumina) indicated that two thirds (6 of 8) of the recurrent parasites resulted from heterologous relapses whose 50% are from by sibling/recombinant clones. Conclusions: No evidence of CQ resistance was observed. Our data suggest that P. vivax antimalarial drug resistance is likely overestimated and that the current guidelines for clinical drug studies of P. vivax malaria need to be revised.
Overview
CoChat Summary
TL;DR
In 40 patients with PCR-confirmed *Plasmodium vivax* malaria in northeastern Cambodia, standard chloroquine cleared blood-stage parasites and no evidence of chloroquine resistance was found. Frequent recurrences occurred after drug levels fell below the 100 ng/mL threshold and were genetically consistent with relapses rather than recrudescence, suggesting prior CQ resistance estimates may be overestimated.
Key findings
- All *P. vivax* parasites were cleared by day 3 by microscopy or day 6 by real-time PCR; parasite clearance half-lives ranged from 2 to 7 hours, except for 1 patient with an 11-hour half-life.
- In 10 polyclonal infections among relocated patients, allele frequencies at variable positions were highly correlated before and 8 hours after CQ treatment (e.g., R² > 0.98 for all individuals between 0 and 8 hours), indicating all clones were cleared at similar rates; 9 of 10 had no SNP with a significant allele-frequency change.
- Recurrences occurred in 24 of 40 patients; mean CQ concentration on the day of recurrence was 42.6 ng/mL (range, 10.5–102.7 ng/mL), with all but 1 patient below the 100 ng/mL resistance threshold. Ten symptomatic recurrences cleared within 48 hours after a second CQ regimen.
- Genotyping (128 SNPs) and whole-genome sequencing indicated two thirds (6 of 8) of recurrent parasites resulted from heterologous relapses, 50% of which were from sibling/recombinant clones; candidate CQ-resistance polymorphisms were observed in >70% of CQ-susceptible isolates, indicating they are not causally associated with CQ resistance.
Methods
- Prospective, open-label drug efficacy study in Ratanakiri Province, Cambodia, in 2014; 40 patients with real-time PCR-confirmed *P. vivax* monoinfection, aged ≥15 years, were treated with a supervised 3-day regimen of CQ (30 mg/kg); 20 patients were relocated to a malaria-transmission-free area and 20 were nonrelocated, with 2-month follow-up.
- Follow-up included frequent clinical examinations and capillary blood sampling for microscopy, real-time PCR, CQ and N-desethyl chloroquine concentration measurement by liquid chromatography-tandem mass spectrometry, 128-SNP genotyping, and whole-genome sequencing (Illumina); parasite clearance rates were estimated with the Parasite Clearance Estimator.
- Statistical comparisons used Mann-Whitney or Kruskal-Wallis tests for nonparametric comparisons and χ² or Fisher exact tests for proportions; genomic analyses are detailed in Appendix 1, with P < .05 considered statistically significant.
Limitations
- Stated: the authors note the small number of patients enrolled in 2014 (8 of 46 in 2009 vs 0 of 40 in 2014; P = .02) and state that the study needs replication and validation in larger cohorts and other settings, such as high-transmission areas.
- Stated: the genomic tools remain limited because they cannot differentiate relapse resulting from homologous parasite populations from recrudescence resulting from incomplete clearance of the primary asexual parasitemia.
- Evident: the study was conducted at a single site with a 2-month follow-up; patients did not receive primaquine because it is not currently recommended by Cambodia’s National Malaria Control Program in the absence of available G6PD testing, so hypnozoite burden was not directly treated or measured.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 17 Not checked · 51 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, we observed a high proportion of recurrence in the weeks following apparently successful treatment.”
§ Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Four patients had submicroscopic P. vivax parasites only detected by real-time PCR.”
§ Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria > P. vivax Recurrences Were Frequent After CQ Treatment
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Allele frequencies at variable positions were highly correlated between consecutive time points (eg, R 2 > 0.98 for all individuals between 0 and 8 hours after treatment), indicating similar susceptibility of all clones to CQ (Figure 1 and Supplementary Table 2).”
§ Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria > All Clones Were Cleared at Similar Rates by CQ in Polyclonal Infections
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Two reasons could explain the differences of CQ treatment failure rates observed between our study and a previous report [12], although the small number of patients enrolled in 2014 (8 of 46 in 2009 vs 0 of 40 in 2014; P = .02).”
§ Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria > DISCUSSION
What the sources say
- Not checked yetcites [12] Leang, 2013, Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010, Antimicrob Agents Chemother source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For patients with recurrences (Figure 3C), the mean drug concentration in blood on the day of recurrence (based on real-time PCR positivity) was 42.6 ng/mL (range, 10.5-102.7 ng/mL).”
§ Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria > Therapeutic Blood Concentration
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
39 more claims
Create a free account to see all 68 claims and to verify the 23 references still open.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 18
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, recent genomic studies have revealed that a proportion of paired P. vivax isolates (from acute and recurrent infections) that would be classified as heterologous using traditional genotyping approaches share homology in large segments of the genome, inferring familial relatedness12–14.”
From Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites (2024) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“two thirds (6 of 8) of the recurrent parasites”
§ Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria > Abstract
Reported 0.6666666666666666 · recomputed 0.75
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria > Abstract
“CQ blood concentrations were below the therapeutic level in all recurrent infections (24 of 40 patients)”
§ Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria > Therapeutic Blood Concentration
“All concentrations were below the threshold used to define CQ resistance (100 ng/mL) [2,15], except in 1 patient, who had a slightly higher drug concentration (V23; 102.7 ng/mL on day 42).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria > P. vivax Recurrences Were Frequent After CQ Treatment
“The time to recurrence varied greatly among patients from day 25 to day 61 according to real-time PCR findings and from day 33 to day 59 according to microscopy findings”
§ Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria > DISCUSSION
“Day of recurrence detection By real-time PCR 42.8 (25-59) 45.7 (28-56) By microscopy 47 (33-61) 48.9 (42-56)”
Citations
Cites
A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010
Gething, P. W., Elyazar, I. R. F., Moyes, C. L., Smith, D. L., Battle, K. E., Guerra, C. A., Patil, A. P., Tatem, A. J., Howes, R. E., Myers, M. F., et al. (2012) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001814 · Cited by 538
Kublin, J. G., Cortese, J. F., Njunju, E. M., G. Mukadam, R. A., Wirima, J. J., Kazembe, P. N., Djimdé, A. A., Kouriba, B., Taylor, T. E., & Plowe, C. V. (2003) · The Journal of Infectious Diseases · doi:10.1086/375419 · Cited by 508
PLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE?
Rieckmann, K. H., Davis, D. R., & Hutton, D. C. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91792-3 · Cited by 501
Antimalarial Drug Resistance: A Threat to Malaria Elimination
Menard, D., & Dondorp, A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025619 · Cited by 499
Return of Chloroquine Antimalarial Efficacy in Malawi
Laufer, M. K., Thesing, P. C., Eddington, N. D., Masonga, R., Dzinjalamala, F. K., Takala, S. L., Taylor, T. E., & Plowe, C. V. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062032 · Cited by 432
Evidence and Implications of Mortality Associated with Acute Plasmodium vivax Malaria
Baird, J. K. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-12 · Cited by 398
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis
Price, R. N., von Seidlein, L., Valecha, N., Nosten, F., Baird, J. K., & White, N. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70855-2 · Cited by 388
Flegg, J. A., Guerin, P. J., White, N. J., & Stepniewska, K. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-339 · Cited by 285
Leang, R., Barrette, A., Bouth, D. M., Menard, D., Abdur, R., Duong, S., & Ringwald, P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00686-12 · Cited by 185
Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900
Rahimi, B. A., Thakkinstian, A., White, N. J., Sirivichayakul, C., Dondorp, A. M., & Chokejindachai, W. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-481 · Cited by 179
Research works printed but not linked: 1
- World Health Organization, 2009, Methods for surveillance of antimalarial drug efficacy
Cited by
Plasmodium vivax in the Era of the Shrinking P. falciparum Map
Price, R. N., Commons, R. J., Battle, K. E., Thriemer, K., & Mendis, K. (2020) · Trends in Parasitology · doi:10.1016/j.pt.2020.03.009 · Cited by 269
Antimalarial Drug Resistance and Novel Targets for Antimalarial Drug Discovery
Shibeshi, M. A., Kifle, Z. D., & Atnafie, S. A. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s279433 · Cited by 186
Resolving the cause of recurrent Plasmodium vivax malaria probabilistically
Taylor, A. R., Watson, J. A., Chu, C. S., Puaprasert, K., Duanguppama, J., Day, N. P. J., Nosten, F., Neafsey, D. E., Buckee, C. O., Imwong, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13412-x · Cited by 118
Malaria Molecular Epidemiology: An Evolutionary Genetics Perspective
Escalante, A. A., & Pacheco, M. A. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.ame-0010-2019 · Cited by 89
Mathematical analysis of reinfection and relapse in malaria dynamics
Ghosh, M., Olaniyi, S., & Obabiyi, O. S. (2020) · Applied Mathematics and Computation · doi:10.1016/j.amc.2020.125044 · Cited by 76
Metadata
- Authors
- Popovici, J., Pierce-Friedrich, L., Kim, S., Bin, S., Run, V., Lek, D., Hee, K. H. D., Lee Soon-U, L., Cannon, M. V., Serre, D., & Menard, D.
- Affiliations
- Institut Pasteur (FR)
- Genomic Medicine Institute, Cleveland Clinic, Ohio
- Cambodia National Malaria Center (KH)
- National University of Singapore
- University of Maryland, Baltimore (US)
- Malaria Molecular Epidemiology Unit, Institut Pasteur in Cambodia, Phnom Penh
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-08-09
- Volume
- 219
- Issue
- 2
- Pages
- 315-322
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC6306015
- OpenAlex
- W2886136603
- Cited by
- 59
- References
- 30
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 13 · 2021: 8 · 2020: 9 · 2019: 4 · 2018: 1
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (R01 AI103228)
- Case Western Reserve University (T32 A107024)
- Institut Pasteur (2014–490)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
- Life Sciences › Immunology and Microbiology › Parasitology › Bird parasitology and diseases
- Keywords
- Plasmodium vivax, chloroquine, antimalarial drug resistance, relapse, reinfection, treatment failure, parasite genotyping, whole genome sequencing, polyclonal infection, Cambodia
- MeSH terms
- Whole Genome Sequencing, Adolescent, Adult, Antimalarials, Cambodia, Chloroquine, Drug Resistance, Female, Genotype, Humans, Male, Middle Aged, Plasmodium vivax, Recurrence, Malaria, Vivax, Treatment Failure, Sequence Analysis, DNA, Polymorphism, Single Nucleotide, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria. https://app.cochat.ai/papers/10.1093/infdis/jiy484
- The paper
- Popovici, J., Pierce-Friedrich, L., Kim, S., Bin, S., Run, V., Lek, D., Hee, K. H. D., Lee Soon-U, L., Cannon, M. V., Serre, D., & Menard, D. (2019). Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy for Plasmodium vivax Malaria. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiy484
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.